Silo Pharma (SILO) to Release Earnings on Wednesday

Silo Pharma (NASDAQ:SILO) is expected to announce its results after the market closes on Wednesday, September 2nd. Analysts expect Silo Pharma to announce earnings of ($0.32) per share and revenue of $0.0180 million for the quarter.

Silo Pharma (NASDAQ:SILO) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.44). Silo Pharma had a negative net margin of 6,726.39% and a negative return on equity of 81.75%.

Silo Pharma Stock Performance

Shares of SILO stock opened at $2.48 on Tuesday. Silo Pharma has a 52-week low of $2.43 and a 52-week high of $15.15. The stock has a market cap of $3.94 million, a price-to-earnings ratio of -0.57 and a beta of 0.71. The firm has a fifty day moving average of $4.50 and a 200-day moving average of $5.39.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its stake in shares of Silo Pharma by 134.6% in the 4th quarter. Geode Capital Management LLC now owns 92,905 shares of the company’s stock valued at $32,000 after purchasing an additional 53,309 shares in the last quarter. Virtu Financial LLC bought a new stake in shares of Silo Pharma in the 3rd quarter worth about $74,000. Finally, DRW Securities LLC acquired a new stake in shares of Silo Pharma during the 4th quarter worth about $113,000. 5.58% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered shares of Silo Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

About Silo Pharma

Silo Pharma, Inc (NASDAQ:SILO) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel psychedelic and related synthetic therapies. Headquartered in New York City, the company applies proprietary chemistry and targeted drug delivery approaches to advance candidates that address critical unmet needs across oncology, neurology and mental health.

The company’s preclinical and early-stage clinical pipeline comprises several programs that explore serotonin receptor modulators, synthetic analogs of classic psychoactive compounds and neuroprotective agents.